Cullinan Therapeutics Q3 net loss $40.6M; cash $639M; CLN-978 IND cleared for SLE Phase 1

Cullinan Therapeutics, Inc.

2024-Q3 EPS reported -$2.30

Net loss $40.6M ($0.69/sh) vs $39.2M ($0.91/sh) in Q3 2023; cash $639M provides runway to 2028.
CLN-978 (SLE) IND cleared in US and Australia; Phase 1 starts; initial data expected Q4 2025.
Zipalertinib pivotal Phase 2b enrollment completed ahead of schedule; results mid-2025.
CLN-619 expansion data in endometrial/cervical cancers expected Q2 2025; patent issued to 2041.
R&D expense $35.5M, G&A $13.3M; both increased YoY from $33.8M and $11.0M respectively.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.